Location History:
- Québec, CA (2019)
- Saint-Lambert, CA (2024)
Company Filing History:
2 out of 183 
1 out of 14 Years Active: 2019-2024
Title: The Innovations of Jean-Sébastien Delisle
Introduction
Jean-Sébastien Delisle is a notable inventor based in Québec, Canada. He has made significant contributions to the field of immunotherapy, particularly through his research on minor histocompatibility antigens. His work has implications for the treatment of hematologic cancers, such as leukemia.
Latest Patents
Delisle holds a patent for "Minor histocompatibility antigens and uses thereof." This patent describes novel minor histocompatibility antigens (MiHAs) that were selected based on two key features: they are encoded by loci with a minor allele frequency (MAF) of at least 0.05, and they exhibit adequate tissue distribution. The patent also details compositions, nucleic acids, and cells related to these novel MiHAs. Furthermore, it discloses the use of these MiHAs in applications related to cancer immunotherapy.
Career Highlights
Throughout his career, Delisle has worked with esteemed institutions, including Université de Montréal and Rsem, Limited Partnership. His research has focused on the intersection of genetics and cancer treatment, contributing to advancements in immunotherapy.
Collaborations
Delisle has collaborated with notable colleagues, including Claude Perreault and Diana Paola Granados. These partnerships have enriched his research and expanded the impact of his innovations in the field.
Conclusion
Jean-Sébastien Delisle's work in the development of minor histocompatibility antigens represents a significant advancement in cancer immunotherapy. His contributions continue to influence the landscape of medical research and treatment options for hematologic cancers.